Indeed, an interesting study on 181 pretreatment melanoma samples showed that a loss of MCH-I is closely related to CTLA-4 inhibitor resistance, while higher levels of MCH-II seem to increase the responsiveness to PD-1 inhibitors (Rodig et al., 2018). Here, PDCD1 is linked to melanoma.